APPLICATIONS

Gives Pharmaceutical and Life Sciences Researchers Test-Drive for Solution that Speeds Run Time and Ensures Accuracy -- ASPEED Software Corporation, the company that is parallelizing and distributing computationally intense applications, is offering trial copies of its ACCELLERANT for NONMEM, providing pharmaceutical and life sciences researchers an opportunity to evaluate a unique parallelization approach that reduces the elapsed run time of long-running models. ACCELLERANT for NONMEM, released last month, is the only solution that allows existing individual NONMEM runs to leverage the substantial performance benefits of grid, cluster, multiprocessor and other parallel distributed computing environments – while ensuring the full integrity of the current application. As a transparent add-on to existing NONMEM software programs that researchers, pharmaceutical companies and life sciences organizations rely on for drug discovery, ACCELLERANT provides, depending on the model, up to a 75 percent run-time reduction for single long running models. “In the race to turn innovative discoveries into life-saving drugs and treatments, NONMEM is the backbone for safer and more reliable evaluations,” said Kurt Ziegler, evp of development for ASPEED Software. “Until now, researchers using this software were unable to reduce the elapsed time of long running models without altering the underlying logic and blending the results together. Our approach to accelerating NONMEM eliminates the manual and complexities associated with these efforts. – allowing researchers to speed the time to answers, while ensuring same – or better – results as sequential runs.” To download the free trial version of ACCELLERANT for NONMEM, visit its Web site. The solution is fully compatible with ICON/GloboMax’s NOMEM and supported for Windows, Linux and Unix platforms.